| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contai... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Sana Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on June 4, 2026. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Mee... |
| 15 May 2026 |
8-K: Other Events
On May 15, 2026, Sana Biotechnology, Inc. (the “Company”) announced that it had sold an aggregate of 21,607,878 shares of its common stock, for aggregate net proceeds of approximately $69.0 million, pursuant to its amended and restated s... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 |
| 24 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
In order to achieve a more equal balance of director membership among the three classes of the Board of Directors (“Board”) of Sana Biotechnology, Inc. (the “Company”) in accordance with the Company’s Amended and Restated Certificate of ... |
| 13 Apr 2026 |
8-K: Other Events
This Stock Purchase Agreement (this “Agreement”) is made as of April 10, 2026 (the “Effective Date”), by and between Sana Biotechnology, Inc., a Delaware corporation (the “Company”), and Mayo Clinic, a Minnesota non-profit corporation (t... |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and... |
| 17 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Sana Biotechnology, Inc. (the “Company”), is pleased to offer you full-time employment in the position of Executive Vice President, Chief Financial Officer, effective as of February 17, 2026 (the date you actually commence employment, yo... |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contai... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced increased focus on type 1 diabetes and in vivo CAR T programs |
| 05 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Sana Biotechnology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Current Report”) to disclose the planned retirement of Bernard J. Cassidy from his role as Executive Vice President, General Counsel, and Corporate... |
| 29 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 28, 2025, Mary Agnes Wilderotter notified Sana Biotechnology, Inc. (“Sana”) of her decision to resign from the Board of Directors (“Board”) of Sana Biotechnology, Inc. (“Sana”), including from her positions as Chairperson of th... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and per... |
| 07 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Sana Biotechnology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “U... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Other Events
The information set forth in Item 8.01 under the caption “Certain Preliminary Financial Information (Unaudited)” is incorporated into this Item 2.02 by reference. |
| 23 Jun 2025 |
8-K: Other Events
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Sana Biotechnology, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) on June 5, 2025. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Mee... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Sana Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
Loading...